Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EBT (2020 - 2025)

Historic EBT for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.

  • Oncology Institute's EBT fell 242.66% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.4 million, marking a year-over-year increase of 586.54%. This contributed to the annual value of -$64.7 million for FY2024, which is 2219.03% up from last year.
  • As of Q3 2025, Oncology Institute's EBT stood at -$16.5 million, which was down 242.66% from -$17.1 million recorded in Q2 2025.
  • Over the past 5 years, Oncology Institute's EBT peaked at $19.5 million during Q1 2022, and registered a low of -$30.0 million during Q1 2023.
  • Its 5-year average for EBT is -$11.2 million, with a median of -$15.5 million in 2024.
  • In the last 5 years, Oncology Institute's EBT soared by 260205.66% in 2022 and then crashed by 54062.27% in 2023.
  • Quarter analysis of 5 years shows Oncology Institute's EBT stood at -$12.6 million in 2021, then rose by 9.9% to -$11.4 million in 2022, then crashed by 67.65% to -$19.1 million in 2023, then surged by 30.87% to -$13.2 million in 2024, then fell by 25.2% to -$16.5 million in 2025.
  • Its EBT stands at -$16.5 million for Q3 2025, versus -$17.1 million for Q2 2025 and -$19.6 million for Q1 2025.